03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Clinician · Diabetes
Michael Radin: no photograph is held, so the clinician plate is shown instead.
Clinician
Michael Radin
M.D., executive medical director, Novo Nordisk
1
0
0
0
1
0
0
May 2026JuneJulyAugSeptOctNovto date
2
press citations on 1 topic since 1 May 2026 · last quoted 29 Sept 2026
02 Quoted on · 1 of 29 topics
Michael Radin: key facts
- Kind of voice
- Clinician
- Role
- M.D., executive medical director, Novo Nordisk
- Quoted on
- Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 29 Sept 2026
- First quoted
- 1 May 2026
04 On the record · press
What Michael Radin has said
By outlet · linked articles
- fiercepharma.com2
Where Michael Radin has been quoted
- 01Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milanfiercepharma.com · 29 Sept 2026
- 02Novo Nordisk's Rybelsus officially retired in US as 'Ozempic pill' takes branding center stagefiercepharma.com · 1 May 2026
Verbatim
“cardiovascular risk should also remain an important consideration”
“With this new formulation, we were able to improve the absorption, if you will, the bioavailability of semaglutide.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.